Valuation: Mangalam Drugs & Organics Limited

Market Cap 509M 5.35M 4.81M 4.49M 4.07M 7.64M 7.68M 53.86M 21.03M 264M 20.08M 19.65M 850M P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 1.63B 17.12M 15.4M 14.37M 13.02M 24.45M 24.6M 172M 67.33M 846M 64.29M 62.9M 2.72B EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
08-17 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
08-12 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
05-14 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
04-17 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
04-16 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
03-26 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
03-17 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
03-17 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
03-17 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
03-17 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
02-06 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
02-06 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day+1.22%
1 week-1.96%
Current month+5.53%
1 month-11.03%
3 months+18.31%
6 months+5.60%
Current year+17.92%
1 week 30.5
Extreme 30.5
34.62
1 month 28
Extreme 28
34.95
Current year 25.7
Extreme 25.7
54.4
1 year 22.8
Extreme 22.8
73
3 years 22.8
Extreme 22.8
144.99
5 years 22.8
Extreme 22.8
173
10 years 20.65
Extreme 20.65
225.7
Manager TitleAgeSince
Chief Executive Officer 73 2011-09-29
Director of Finance/CFO - 2026-02-05
Compliance Officer 27 2026-03-31
Director TitleAgeSince
Chairman 73 2010-02-01
Director/Board Member 75 2015-02-04
Director/Board Member 38 2018-05-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%-1.96% - - 5.3M
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.84%+1.90%+33.13%+59.88% 415.87B
Weighted average by Cap. +2.66%+1.53%+36.79%+68.68%

Financials

2025 2026
Net sales 3.18B 33.37M 30M 28M 25.38M 47.65M 47.94M 336M 131M 1.65B 125M 123M 5.3B 2.32B 24.39M 21.93M 20.47M 18.55M 34.83M 35.04M 246M 95.91M 1.2B 91.58M 89.6M 3.87B
Net income 67.21M 706K 635K 593K 537K 1.01M 1.01M 7.11M 2.78M 34.88M 2.65M 2.59M 112M -444M -4.67M -4.19M -3.91M -3.55M -6.66M -6.7M -46.98M -18.34M -230M -17.52M -17.14M -741M
Net Debt 936M 9.84M 8.85M 8.26M 7.48M 14.05M 14.14M 99.08M 38.69M 486M 36.94M 36.14M 1.56B 1.12B 11.77M 10.59M 9.88M 8.95M 16.81M 16.92M 119M 46.3M 582M 44.21M 43.25M 1.87B
Projected Income Statement - Annual - Mangalam Drugs & Organics Limited
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
26-10-14 ₹32.44 +1.22% 17,873
26-10-13 ₹32.05 +0.82% 16,833
26-10-12 ₹31.79 +2.35% 16,254
26-10-09 ₹31.06 -1.33% 181,357
26-10-08 ₹31.48 -4.87% 27,243